Beta-Blocker Toxicity Medication

  • Author: Adhi Sharma, MD; Chief Editor: Asim Tarabar, MD   more...
 
Updated: Oct 27, 2011
 

Medication Summary

Because of the nature of overdoses, definitive evidence-based recommendations are limited. However, commonly used agents include crystalloids, atropine, pressors with catecholamine action, glucagon, and phosphodiesterase inhibitors.

Next

Gastrointestinal Tract Decontaminants

Class Summary

These agents are used to minimize the absorption of ingested compound.

Activated charcoal (Requa Activated Charcoal, EZ-Char, Actidose-Aqua)

 

Although most useful if administered within 4 hours of ingestion, repeated doses may be used, especially with ingestions of sustained-released agents. Limited outcome studies exist, especially when activated charcoal is used more than 1 hour postingestion. No clinical data exist to suggest a benefit of multiple-dose activated charcoal with beta-blockers, even sustained-release preparations.

The dose may be repeated q4h at 0.5 g/kg. Alternate with use of a cathartic; monitor for active bowel sounds.

Previous
Next

Cardiovascular agents

Class Summary

These agents are used for symptomatic bradycardia and/or hypotension. Catecholamines are considered a primary treatment for more severe cases of beta-blocker poisoning.

Atropine IV/IM (Atropine Care, Isopto Atropine)

 

Atropine enhances sinus node automaticity by blocking the effects of acetylcholine at the atrioventricular (AV) node, decreasing refractory time and speeding conduction through the AV node.

Glucagon (GlucaGen)

 

Glucagon is considered the drug of choice for beta-blocker toxicity by many authors. This agent stimulates production of cyclic adenosine monophosphate (cAMP) through nonadrenergic pathways. Result is enhanced myocardial contractility, heart rate, and AV conduction.

An upper dose limit has not been established.

Epinephrine (Adrenalin)

 

Agents with combined alpha- and beta-selective properties may be necessary to maintain blood pressure. A beta-agonist may competitively antagonize the effect of the beta-blocker.

The amount of beta-agonist required might be several orders of magnitude above those recommended in standard Advanced Cardiac Life Support (ACLS) protocols

Dopamine

 

Agents with combined alpha- and beta-selective properties may be necessary to maintain blood pressure. A beta-agonist may competitively antagonize the effect of the beta-blocker.

The amount of beta-agonist required might be several orders of magnitude above those recommended in standard ACLS protocols. In a canine model, the doses of isoproterenol and dopamine had to be increased 15 and 5 times, respectively, in order to effect similar hemodynamic changes that occurred before beta-blockade with 1 mg/kg of propranolol.

Inamrinone

 

Inamrinone produces vasodilation and increases the inotropic state. Tachycardia occurs more commonly with this agent than with dobutamine. Inamrinone may exacerbate myocardial ischemia. Case reports describe it as effective when other agents fail.

Calcium chloride

 

Calcium chloride moderates nerve and muscle performance by regulating the action potential excitation threshold. At high doses, propranolol blocks the calcium channels that may induce asystole, AV block, and depressed myocardial contraction.

Magnesium sulfate

 

Magnesium sulfate acts as antiarrhythmic agent and diminishes the frequency of premature ventricular contractions (PVCs), particularly those secondary to acute ischemia. This agent is used to treat torsade de pointes associated with sotalol intoxication.

Insulin regular human (Novolin, Humulin)

 

High-dose insulin therapy is highly investigational but should be considered when other therapies are failing.[5] Dextrose infusion of 10-75 g/h may be required. Consult a toxicologist if this regimen is considered.

Previous
Next

Benzodiazepines

Class Summary

These agents prevent seizure recurrence and terminate clinical and electrical seizure activity.

Lorazepam (Ativan)

 

Benzodiazepines are considered the treatment of choice for beta-blocker–induced seizures. Of the benzodiazepines, lorazepam has the longest anticonvulsant activity (4-6 h) and is preferred. By increasing the action of GABA, which is a major inhibitory neurotransmitter in the brain, all levels of CNS, including limbic and reticular formation, may be depressed. It is important to monitor the patient's blood pressure after administering dose. Adjust as needed.

Diazepam (Valium, Diastat)

 

Diazepam depresses all levels of CNS (eg, limbic and reticular formation), possibly by increasing activity of GABA. It is considered second-line therapy for seizures.

Phenobarbital

 

Phonobarbital may be necessary to control status epilepticus.

Previous
 
Contributor Information and Disclosures
Author

Adhi Sharma, MD  Assistant Professor, Department of Emergency Medicine, Elmhurst Hospital Center, Mount Sinai School of Medicine; Chairman, Department of Emergency Medicine, Good Samaritan Hospital Medical Center; Medical Toxicology Consultant, New York City Department of Health and Poison Control Center

Adhi Sharma, MD is a member of the following medical societies: American College of Clinical Toxicologists, American College of Emergency Physicians, and American College of Medical Toxicology

Disclosure: Nothing to disclose.

Coauthor(s)

Lemeneh Tefera, MD, FAAEM  Attending Physician, Department of Emergency Medicine, Beth Israel Medical Center

Lemeneh Tefera, MD, FAAEM is a member of the following medical societies: American Academy of Emergency Medicine

Disclosure: Nothing to disclose.

Aman Aminzay, MD  Attending Physician, Department of Emergency Medicine, Beth Israel Medical Center, Albert Einstein College of Medicine

Aman Aminzay, MD is a member of the following medical societies: American College of Emergency Physicians

Disclosure: Nothing to disclose.

Chief Editor

Asim Tarabar, MD  Assistant Professor, Director, Medical Toxicology, Department of Emergency Medicine, Yale University School of Medicine; Consulting Staff, Department of Emergency Medicine, Yale-New Haven Hospital

Disclosure: Nothing to disclose.

Additional Contributors

John G Benitez, MD, MPH, FACMT, FAACT, FACPM, FAAEM, Associate Professor, Department of Medicine, Medical Toxicology, Vanderbilt University Medical Center; Managing Director, Tennessee Poison Center

John G Benitez, MD, MPH, FACMT, FAACT, FACPM, FAAEM, is a member of the following medical societies: American Academy of Clinical Toxicology, American Academy of Emergency Medicine, American College of Medical Toxicology, American College of Preventive Medicine, Society for Academic Emergency Medicine, Undersea and Hyperbaric Medical Society, and Wilderness Medical Society

Disclosure: Nothing to disclose.

David C Lee, MD Research Director, Department of Emergency Medicine, Associate Professor, North Shore University Hospital and New York University Medical School

David C Lee, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American College of Medical Toxicology, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

John T VanDeVoort, PharmD Regional Director of Pharmacy, Sacred Heart & St. Joseph's Hospitals

John T VanDeVoort, PharmD is a member of the following medical societies: American Society of Health-System Pharmacists

Disclosure: Nothing to disclose.

Acknowledgments

The authors and editors of Medscape Reference gratefully acknowledge the medical review of this article by Lada Kokan, MD.

References
  1. Bronstein AC, Spyker DA, Cantilena LR Jr, Green JL, Rumack BH, Heard SE. 2007 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 25th Annual Report. Clin Toxicol (Phila). Dec 2008;46(10):927-1057. [Medline].

  2. Watson WA, Litovitz TL, Rodgers GC Jr, et al. 2004 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. Sep 2005;23(5):589-666. [Medline].

  3. Wax PM, Erdman AR, Chyka PA, et al. beta-blocker ingestion: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2005;43(3):131-46. [Medline].

  4. Position statement and practice guidelines on the use of multi-dose activated charcoal in the treatment of acute poisoning. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. J Toxicol Clin Toxicol. 1999;37(6):731-51.

  5. Engebretsen KM, Kaczmarek KM, Morgan J, Holger JS. High-dose insulin therapy in beta-blocker and calcium channel-blocker poisoning. Clin Toxicol (Phila). Apr 2011;49(4):277-83. [Medline].

  6. Weinberg GL, VadeBoncouer T, Ramaraju GA, Garcia-Amaro MF, Cwik MJ. Pretreatment or resuscitation with a lipid infusion shifts the dose-response to bupivacaine-induced asystole in rats. Anesthesiology. Apr 1998;88(4):1071-5. [Medline].

  7. Weinberg G, Ripper R, Feinstein DL, Hoffman W. Lipid emulsion infusion rescues dogs from bupivacaine-induced cardiac toxicity. Reg Anesth Pain Med. May-Jun 2003;28(3):198-202. [Medline].

  8. Rosenblatt MA, Abel M, Fischer GW, Itzkovich CJ, Eisenkraft JB. Successful use of a 20% lipid emulsion to resuscitate a patient after a presumed bupivacaine-related cardiac arrest. Anesthesiology. Jul 2006;105(1):217-8. [Medline].

  9. Litz RJ, Popp M, Stehr SN, Koch T. Successful resuscitation of a patient with ropivacaine-induced asystole after axillary plexus block using lipid infusion. Anaesthesia. Aug 2006;61(8):800-1. [Medline].

  10. Foxall G, McCahon R, Lamb J, Hardman JG, Bedforth NM. Levobupivacaine-induced seizures and cardiovascular collapse treated with Intralipid. Anaesthesia. May 2007;62(5):516-8. [Medline].

  11. Cave G, Harvey MG, Castle CD. The role of fat emulsion therapy in a rodent model of propranolol toxicity: a preliminary study. J Med Toxicol. Mar 2006;2(1):4-7. [Medline].

  12. Bania TC, Chu J, Perez E, Su M, Hahn IH. Hemodynamic effects of intravenous fat emulsion in an animal model of severe verapamil toxicity resuscitated with atropine, calcium, and saline. Acad Emerg Med. Feb 2007;14(2):105-11. [Medline].

Previous
Next
 
Bradycardia is evident on a rhythm strip from a 48-year-old man who presented to the emergency department after a generalized tonic-clonic seizure. The patient was also hypotensive (82/55 mm Hg). The family reported that he was taking a medication, which proved to be propranolol, for a rapid heart rate. Propranolol is the most common beta-blocker involved in severe beta-blocker poisoning. It is nonselective and has membrane-stabilizing effects that are responsible for CNS depression, seizures, and prolongation of the QRS complex.
Sotalol is associated with the rhythm shown below in both therapeutic doses and toxic ingestions. Sotalol has been used as a class III antiarrhythmic agent to control dangerous ventricular tachydysrhythmias in some individuals. It causes polymorphic ventricular tachycardia (torsade de pointes) in approximately 4% of patients. Rarely, prolongation of the QT interval has been reported with propranolol.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.